Abstract-Reactive oxygen species (ROS) contribute to the pathogenesis of atherosclerosis in part by promoting vascular smooth muscle cell (VSMC) growth. Previously we demonstrated that cyclophilin A (CyPA) is a secreted oxidative stress-induced factor (SOXF) that promotes inflammation, VSMC growth, and endothelial cell apoptosis. However, the mechanisms that regulate CyPA secretion are unknown. In this study, we hypothesized that ROS-induced CyPA secretion from VSMC requires a highly regulated process of vesicle transport, docking, and fusion at the plasma membrane. Conditioned medium and plasma membrane sheets were prepared by exposing VSMC to 1 mol/L LY83583, which generates intracellular superoxide. A vesicular transport mechanism was confirmed by colocalization at the plasma membrane with vesicle-associated membrane protein (VAMP). CyPA transport to the plasma membrane and secretion were significantly increased by LY83583. Reduction of VAMP-2 expression by small interfering RNA inhibited LY83583-induced CyPA secretion. Pretreatment with 3 mol/L cytochalasin D, an actin depolymerizing agent, abrogated CyPA secretion. Infection with dominant-negative RhoA and Cdc42 adenovirus inhibited CyPA secretion by 72% and 63%, respectively, whereas dominant-negative Rac1 had a small effect (11% 
V ascular smooth muscle cells (VSMC) respond to alternations in blood pressure and tissue demands by diverse growth responses that include proliferation, hypertrophy, and apoptosis. Abnormal VSMC growth contributes to the pathogenesis of atherosclerosis and restenosis. Increasing evidence indicates that autocrine and paracrine growth factors modulate VSMC growth in part by mediating secretion of growth factors, 1 such as epiregulin, 2 platelet-derived growth factor, 3, 4 and transforming growth factor-␤. 5 Reactive oxygen species (ROS) have been shown to be key growth factors both by direct effects or protein synthesis and cell growth pathways 6, 7 and by stimulating autocrine/paracrine growth pathways.
ROS induce VSMC growth 6 by activating kinases such as extracellular signal-regulated kinases (ERK) 1/2 7 and p38. 8 In a previous study, we observed that stimulation of VSMC with the napthoquinolinedione LY83583, an intracellular superoxide generator, resulted in a biphasic activation of ERK1/2: a rapid phase of ERK1/2 activation was observed at 5 to 10 minutes and late phase was observed at 2 hours. 9 These results led us to explore the existence of specific mediators of ROS that participate in the late phase activation of ERK1/2 by autocrine/paracrine growth mechanisms. Recently, we demonstrated that cyclophilin A (CyPA) is a secreted oxidative stress-induced factor (SOXF) that stimulates ERK1/2 and promotes VSMC growth and endothelial cell apoptosis. 10, 11 CyPA is a ubiquitously distributed and abundantly expressed intracellular protein that has peptidyl-prolyl cis-trans isomerase activity. 12 CyPA has multiple intracellular functions, including roles as immunophilins that interact with calcineurin, as components of a caveolin-cholesterol-cyclophilin complex, and as components of the cell cycle. 13 Evolving data point to novel extracellular roles of CyPA in inflammatory diseases such as rheumatoid arthritis 14 and atherosclerosis. 10, 11 Extracellular CyPA stimulates IB␣ phosphorylation and nuclear factor B activation and induces expression of adhesion molecules including E-selectin and vascular cell adhesion molecule-1. 11 These results suggest that secreted CyPA acts as an inflammatory mediator that may be involved in the pathogenesis of atherosclerosis. However, the mechanisms that regulate CyPA secretion are unknown.
In this study, we hypothesized that ROS-induced CyPA secretion requires a highly regulated process of vesicle transport, docking and fusion at the plasma membrane. We show that Rho GTPase signaling, actin remodeling, and myosin II activation are involved in CyPA secretion. Furthermore, we show that 3 hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors dramatically decrease ROS-induced CyPA secretion by VSMC.
Materials and Methods

Reagents and Chemicals
LY83583 and rabbit VAMP-2 antibody were from Sigma (St Louis, Mo); jasplakinolide, cytochalasin D, Y27632, blebbistatin, and simvastatin were from Calbiochem (La Jolla, Calif); rabbit CyPA polyclonal antibody was from BIOMOL Research Laboratories Inc (Plymouth Meeting, Pa); and goat vesicle-associated membrane protein (VAMP)-1/2 polyclonal and mouse c-myc monoclonal antibodies were from Santa Cruz Biotechnology (Santa Cruz, Calif).
Cell Culture and Treatments
VSMC were isolated from 200 to 250 g male Harlan SpragueDawley rats and maintained in DMEM containing 10% FBS at 37°C in a humidified atmosphere of 5% CO 2 /95% air, as described previously. 15 Passages 5 to 14 VSMC at 70% to 80% confluence were growth arrested by incubation in serum-free DMEM for 24 hours and stimulated by 1 mol/L M LY83583 or DMEM for 2 hours. For the inhibitor studies, cells were pretreated with 0. 
Preparation of Conditioned Medium
Conditioned medium from LY83583-stimulated cells or control medium from DMEM-incubated cells was collected and centrifuged for 10 minutes at 800g to remove cell debris. The medium was concentrated 100-fold by using a Centricon Plus-20 filter (Millipore Corporation, Bedford, Mass) to yield concentrated conditioned medium.
Plasma Membrane Sheet Assay
Preparation of plasma membrane sheets and immunofluorescence were performed as described previously. 16 A detailed description of plasma membrane sheet assay is available in the online data supplement at http://circres.ahajournals.org.
Subcellular Fractionation
CyPA-containing vesicles were separated as described previously. 17, 18 (For details, see the online data supplement.)
RNA Interference
VSMC were treated with small interfering RNA (siRNA) against rat VAMP-2 coding region. The target sequences were 5Ј-AACAAGTGCAGCCAAGCTCAA-3Ј for rat VAMP-2 and 5Ј-AATTCTCCGAACGTGTCACGT-3Ј for control nonsilencing siRNA (QIAGEN-Xeragon). VSMC at 50% confluence were transfected with 40 nmol/L of siRNA using Lipofectamine 2000 (Invitrogen) for 4 hours. Cells were harvested 48 hours later and used for experiments.
Adenovirus Transfection
Cells were infected with dominant-negative c-myc tagged N19RhoA, N17Cdc42, and N17Rac1 mutant-expressing adenoviruses 19 at a multiplicity of infection of 50. ␤-Galactosidase (LacZ)-expressing adenovirus (50 multiplicity of infection) was used as a control.
Western Blot Analysis
The membrane was blocked for 2 hours at room temperature with 5% milk. The blot was incubated with the primary antibody (1:1000) overnight at 4°C, followed by incubation for 1 hour with horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were visualized using ECL (Amersham Pharmacia Biotech). Analysis of autoradiograms was performed by scanning densitometry and processing with NIH image analysis software.
Statistical Analysis
All immunofluorescent images and immunoblots are representative of at least three to 4 experiments. Quantitative data are presented as meanϮSE. Differences were analyzed with 1-way ANOVA and post hoc analysis was performed using Bonferroni-Dunn. PϽ0.05 was accepted as a significant difference.
Results
Oxidative Stress Induces Secretion of Cyclophilin A From Vascular Smooth Muscle Cells
We have previously demonstrated that LY83583, an intracellular superoxide generator, induces secretion of CyPA from VSMC. 10 We first examined the time course of CyPA secretion after LY83583 exposure by Western blot analysis of conditioned medium. CyPA secretion was observed following 30 minutes of exposure to LY83583 (1mol/L) with abundant secretion at 120 minutes, whereas the CyPA protein level did not change in total cell lysates ( Figure 1A ).
We postulated that CyPA is secreted through a process requiring vesicle formation. To examine the plasma membrane colocalization of CyPA and vesicular proteins, resulting from LY83583-induced transport of secreted CyPA vesicles, we double-stained isolated plasma membrane sheets 16 with CyPA and VAMP antibodies. Under basal conditions, there was no CyPA immunofluorescence in the plasma membrane ( Figure 1B ). In contrast, LY83583 stimulation significantly increased CyPA immunofluorescence that was maximal at 1 hour ( Figure 1B and 1C) . When the plasma membrane sheets were stained for the scaffolding protein 14-3-3 as a negative control, no obvious expression was observed (data not shown). The colocalization of CyPA with VAMP in the plasma membrane suggests that LY83583 induces transport of CyPA vesicles to the plasma membrane ( Figure 1D ). To confirm further if CyPA is translocated from an intracellular compartment to plasma membrane associated vesicles in response to LY83583 stimulation, VSMC lysates were separated on a sucrose density gradient and CyPA and VAMP-2 detected by Western blot analysis. LY83583 exposure increased the level of CyPA in VAMP-2-enriched vesicle fractions (lanes 11 to 12) from 8.4% of total CyPA in controls to 24.0% in LY83583-exposed VSMC (supplemental Figure I ). VAMP-2 has been shown to play a key role in secretion of synaptic vesicles. 20 Thus we next examined the effect of VAMP-2 gene knockdown on CyPA secretion. Compared with control siRNA, VAMP-2 siRNA significantly inhibited LY83583-induced CyPA secretion (Figure 2 ). VAMP-2 siRNA had no effect on ERK1/2 activation by LY83583 stimulation for 10 minutes (data not shown). These results suggest that VAMP-2 expression and vesicle formation are required for CyPA secretion in VSMC.
Actin Remodeling Is Required for CyPA Secretion
Remodeling of the actin cytoskeleton is involved in intracellular trafficking mechanisms and plays a critical role in regulated secretion. 21 Dynamic actin disassembly and reassembly are necessary for regulated membrane docking and fusion events. 22, 23 To determine whether actin polymerization and depolymerization are involved in CyPA secretion, VSMC were pretreated with the actin polymerizing agent jasplakinolide (0.3 to 3 mol/L) or the depolymerizing agent cytochalasin D (0.3 to 3 mol/L) for 30 minutes before exposure to 1 mol/L LY83583. Both jasplakinolide and cytochalasin D inhibited LY83583-induced CyPA secretion in a dosedependent manner (Figure 3 ).
Rho GTPases Regulate CyPA Secretion
Rho GTPases including RhoA, Cdc42, and Rac1 are well known for their effects on actin cytoskeleton remodeling. To assess the roles of Rho GTPases in CyPA secretion, VSMC were infected with recombinant adenoviruses that express dominant-negative mutants N19RhoA, N17Cdc42, and N17Rac1. Infection with N17Rac1 had only a modest inhibitory effect on CyPA secretion (11%) ( Figure 4A and 4B). In contrast, infection with N19RhoA and N17Cdc42 inhibited CyPA secretion to a large extent compared with control LacZ-expressing adenovirus infected cells (72% and 63%, respectively) ( Figure 4A and 4B). Infection with both N19RhoA and N17Cdc42 had no additive inhibitory effect on CyPA secretion (supplemental Figure II) . Infection with DN19RhoA and N17Cdc42 also inhibited LY83583-induced transport of CyPA to the plasma membrane ( Figure 4C ). These results indicate that RhoA and Cdc42 but not Rac1 are required for LY83583-induced CyPA secretion.
Rho Kinase and Myosin II Activity Are Required for CyPA Secretion
Rho kinase, a downstream effector of Rho, induces myosin II light chain phosphorylation via inactivation of myosin II light chain phosphatase. 24 Phosphorylation of myosin II light chain has been reported to facilitate transport of secretory proteins. 25, 26 To investigate the roles of Rho kinase and myosin II activity in CyPA secretion, VSMC were pretreated with the Rho kinase inhibitor Y27632 (3 to 30 mol/L) or the myosin II inhibitor blebbistatin (1 to 10 mol/L) before exposure to 1 mol/L LY83583. Both Y27632 and blebbistatin inhibited CyPA secretion in a dose-dependent manner ( Figures 5A and  6A, respectively) . Moreover, pretreatment with 30 mol/L Y27632 and 10 mol/L blebbistatin abolished LY83583-induced transport of CyPA to the plasma membrane ( Figures  5B and 6B, respectively) . These results suggest that CyPA secretion is not passive but requires Rho kinase and myosin II activity for secretion.
Simvastatin Inhibits CyPA Secretion
Protein isoprenylation is essential for the function of Rho GTPases. HMG-CoA reductase inhibitors such as statins Figure 1 . LY83583 induces CyPA secretion in VSMC. Growtharrested VSMC were exposed to 1 mol/L LY83583 for the indicated times. A, Conditioned medium (CM) and total cell lysate (TCL) were immunoblotted with antibody to CyPA. Human recombinant CyPA (hrCyPA) was used as a positive control. B, Plasma membrane sheets were prepared as described in Materials and Methods. C, Intensity of fluorescence was quantified by use of computer-imaging software as described in Materials and Methods. Results were normalized to fluorescence intensity at time 0 minutes, which was set to 1.0. The plasma membrane sheets were fixed and stained for CyPA. D, Growth-arrested VSMC were exposed to 1 mol/L LY83583 for 60 minutes. Plasma membrane sheets were prepared and then fixed and stained for CyPA and VAMP1/2. Values are meanϮSE from 3 independent experiments. *PϽ0.05 compared with control. Scale bars, 50 m. prevent isoprenylation and inhibit intracellular signaling mediated by Rho GTPases. 27 To examine the effect of statins on CyPA secretion, VSMC were pretreated with simvastatin (3 to 30 mol/L) before exposure to LY83583. Simvastatin inhibited LY83583-induced CyPA secretion in a dosedependent manner ( Figure 7A ). In addition, pretreatment with 30 mol/L simvastatin abolished LY83583-induced transport of CyPA to the plasma membrane ( Figure 7B ). Because statins exert antioxidant effects, it is possible that simvastatin is working through as an antioxidant property. To evaluate this possibility, we examined the effect of simvastatin on CyPA secretion in N19RhoA infected VSMC. Although pretreatment with 3 or 10 mol/L simvastatin had no additive inhibitory effect, 30 mol/L simvastatin further decreased CyPA secretion (supplemental Figure II) , suggesting that high-dose statins may inhibit ROS-induced CyPA secretion in part by mediating a Rho GTPase-independent pathway (eg, an antioxidant effect). Taken together, these results suggest that LY83583-induced CyPA secretion involves a pathway including Rho GTPases signaling, actin remodeling, and myosin II activation.
Discussion
The major findings in this study are that CyPA is secreted from VSMC via a highly regulated pathway that involves vesicle transport and plasma membrane binding (Figure 8 ). We showed that signaling pathways involving RhoA and Cdc42 for myosin II activation and actin remodeling play a crucial role in ROS-induced CyPA secretion. We also found that statins inhibited CyPA secretion. To our knowledge, these findings are the first to demonstrate the mechanisms for CyPA secretion from VSMC in response to ROS.
Autocrine and paracrine growth mechanisms are important in VSMC growth. 1 Indeed, several growth factors are secreted from VSMC in response to various stimuli. [2] [3] [4] [5] However, the intracellular trafficking mechanisms that regulate secretion of these growth factors are not well understood. The best studied secretory pathway in VSMC involves tissue factor, the initiator of the clotting cascade. Tissue factor is released in microparticles that bud from the VSMC plasma membrane. 28 We harvested medium from LY83583-exposed VSMC and performed high-speed centrifugation (100 000gϫ1 hour) onto a 60% sucrose cushion. Although virtually all of the tissue factor activity (Ͼ95%) has been shown to be precipitated by this technique, 28 we did not find CyPA in microparticles supporting the vesicle pathway described here. This novel secretory pathway for CyPA involves Rho GTPase-myosin II activation/actin remodeling regulated vesicle transport, docking, and fusion process.
Soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptors (SNAREs) play a central role in the RhoA and Cdc42 activity are required for LY83583-induced CyPA secretion. VSMC were infected with recombinant adenoviruses that express dominant-negative mutants N19RhoA, N17Cdc42, and N17Rac1. A, Cells were subsequently exposed to 1 mol/L LY83583 for 2 hours. Conditioned medium (CM) and total cell lysate (TCL) were immunoblotted with antibody to CyPA and c-myc. B, Results were quantified by densitometry of autoradiograms. C, Cells were exposed to 1 mol/L LY83583 for 60 minutes. Plasma membrane sheets were prepared and then fixed and stained for CyPA. Values are meanϮSE from 3 independent experiments. *PϽ0.05 compared with LacZ.
control of membrane traffic events. 29 VAMP/synaptobrevin, a member of SNAREs, together with other SNAREs including syntaxin and SNAP-25 families are required for secretion of synaptic vesicles. 30 In this study, we showed that CyPA transported to the plasma membrane and colocalized with VAMP in response to ROS stimulation (Figure 1) . In addition, gene silencing of VAMP-2 by siRNA significantly inhibited ROS-induced CyPA secretion (Figure 2) . These results support the hypothesis that CyPA is secreted from VSMC through a process requiring vesicle formation.
It has become clear that actin remodeling participates in vesicular trafficking pathways. 21 The involvement of actin polymerization in CyPA secretion was demonstrated by use of cytochalasin D, an actin depolymerizing agent ( Figure  3A) . Consistent with our results, inhibition of secretory vesicle fusion with the plasma membrane by actin depolymerizing agents has been reported. 23 However, actin stabilizing agents such as phallotoxin and jasplakinolide also inhibit vesicle docking with plasma membrane. 22 Indeed, jasplakinolide dose-dependently inhibited CyPA secretion ( Figure 3B ). These observations indicate that regulated disassembly and reorganization of actin cytoskeleton plays an important role in secretory-vesicle trafficking and fusion.
Rho GTPases including RhoA, Cdc42, and Rac1 are key regulators in signaling pathways linked to actin cytoskeletal rearrangement. 31 The Rho GTPases are therefore thought to have a central role in vesicular trafficking pathways by controlling organization of the actin cytoskeleton. In support of this notion, it has been reported that active participation of Rho GTPases is required for secretion. [32] [33] [34] In agreement with these observations, we showed that expression of dominantnegative mutants of RhoA and Cdc42 inhibited ROS-induced CyPA secretion (Figure 4) , suggesting that both RhoA-and Cdc42-dependent signaling events regulate CyPA secretion. Although Rac1 controls the organization of the actin cytoskeleton, expression of dominant-negative Rac1 had only a modest effect on CyPA secretion. A possible explanation for this finding is that the role of Rac1 in secretion is cell specific. 35 Myosin II is involved in secretory mechanisms as a motor for vesicle transport. 25, 26 Regulation of myosin II activity involves multiple cooperative pathways. For example, Rho kinase, a downstream effector of RhoA, mediates myosin II activation via phosphorylation and inactivation of myosin II light chain phosphatase. 24 Recently, the Cdc42 target myotonic dystrophy kinase-related Cdc42 binding kinase was reported to cooperate with Rho kinase in myosin II activation. 36 Our data show that both Y27632, a specific Rho kinase inhibitor, and blebbistatin, an inhibitor of myosin II ATPase activity, inhibited ROS-induced CyPA secretion and transport to the plasma membrane (Figures 5 and 6 ). These results suggest that myosin II-mediated vesicle transport is required for CyPA secretion from VSMC. Recent clinical trials show that statins reduce cardiovascular events, mortality, and progression of atherosclerosis. 37, 38 Some of these beneficial effects of statins appear to be independent of cholesterol lowering, such as inhibiting inflammation and improving endothelial function. 39, 40 Statins prevent isoprenylation of Rho GTPases, thus inhibiting their membrane translocation and activation. 27 Inhibition of Rho GTPases may represent 1 of the cholesterol-independent vascular protective effects of statins. 27 Accordingly, our findings that Rho GTPases play a positive role in secretion mechanisms led us to study the effect of statins on CyPA secretion. We found that simvastatin inhibited ROS-induced transport of CyPA to the plasma membrane and secretion into conditioned medium (Figure 7) . These results are consistent with previous findings that statins prevent secretion in alveolar epithelial cells. 32 Inhibition of ROS-induced CyPA secretion may represent 1 of the vascular protective effects of statins. 
